NCT00661544 - Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

Multiple MyelomaStem Cell Transplantation

Interventions

DRUG

Arsenic Trioxide

Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.

DRUG

Melphalan

Dose Levels 1, 2, \& 3: 100 mg/m2 IV Days -4, -3.

DRUG

Ascorbic Acid

Dose Levels 1, 2, \& 3: 1000 mg IV Days -9 to -3.

Trial Locations (1)

U.T.M.D. Anderson Cancer Center, Houston